Endothelin Receptor Type B (EDNRB) Antibody (FITC)

Background

EDNRB is a G protein-coupled receptor that binds endothelin-1 (ET-1), endothelin-2, and endothelin-3 with equal affinity, playing key roles in vasodilation, endothelial function, and neural crest cell development. EDNRB is primarily expressed on endothelial cells, where its activation stimulates the release of nitric oxide (NO) and prostacyclin, leading to vasodilation and reduced vascular tone. It also mediates endothelin clearance, regulating ET-1 levels in circulation. During development, EDNRB is essential for neural crest cell migration and differentiation, with mutations in EDNRB linked to Hirschsprung’s disease and Waardenburg syndrome. In cardiovascular physiology, EDNRB balances the vasoconstrictive effects of EDNRA by promoting vasodilation and endothelial repair, but its dysregulation can contribute to pulmonary arterial hypertension (PAH) and vascular dysfunction. In cancer, EDNRB expression on tumor cells and stromal cells has been linked to enhanced tumor invasion, metastasis, and angiogenesis, particularly in melanoma and colorectal cancers. EDNRB signaling also modulates immune responses and inflammation in pathological conditions. Therapeutically, selective modulation of EDNRB is being explored to restore vascular function and manage diseases like PAH and specific cancers. EDNRB thus serves as a key regulator of vascular homeostasis, development, and disease progression.